Cost-effectiveness of ocular interventions

Current Opinion in Ophthalmology

Volumn 14, Issue 3, 2003, Pages 132-138

  Busbee, Brandon G ^a,b,c,d   Brown, Gary C ^a   Brown, Melissa M ^a  

^a WILLS EYE HOSPITAL   (United States)

^b TUFTS UNIVERSITY   (United States)

^c OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; AMBLYOPIA; CATARACT; CATARACT EXTRACTION; COST UTILITY ANALYSIS; DIABETIC RETINOPATHY; EYE SURGERY; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETROLENTAL FIBROPLASIA; REVIEW; VITRECTOMY;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HUMANS; OPHTHALMOLOGY; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 0038354864     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200306000-00004     Document Type: Review

References (59)

1. Centers for Medicare and Medicaid Services: Available at: http://cms.hhs.gov/statistics/nhe/projections-2001/highlights.asp. Accessed 2002.
2. World Health Organization Assesses the World's Health Systems: Available at: http://www.who.int/whr/2000/en/pressrelease.htm. Accessed 2000.
3. Oregon Measure 23: Available at: http://www.healthcareforalloregon.org. Accessed 2002.
4. Sackett DL, Straus SE, Richardson WS, et al.: Evidence-Based Medicine. How to Practice and Teach EBM. Philadelphia: Churchill Livingstone; 2000.
5. Beauchamp GR, Bane MC, Stager DR, et al.: A value analysis model applied to the management of amblyopia. Trans Am Ophthalmol Soc 1999, 97:349-367, discussion 367-372.
6. Brown GC: Vision and quality-of-life. Trans Am Ophthalmol Soc 1999, 97:473-511.
7. Brown GC, Brown MM, Sharma S, et al.: Cost-effectiveness of treatment for threshold retinopathy of prematurity. Pediatrics 1999, 104:e47.
8. Brown MM, Brown GC, Sharma S, et al.: Utility values and diabetic retinopathy. Am J Ophthalmol 1999, 128:324-330.
9. Brown GC, Brown MM, Sharma S, et al.: Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000, 14:18-24.
10. Brown GC, Brown MM, Sharma S, et al.: Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000, 107:1374-1380.
11. Brown GC, Brown MM, Sharma S, et al.: Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis. Retina 2000, 20:331-337.
12. Brown GC, Sharma S, Brown MM, et al.: Utility values and age-related macular degeneration. Arch Ophthalmol 2000, 118:47-51.
13. Vijan S, Hofer TP, Hayward RA: Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000, 283:889-896.
14. Brown MM, Brown GC, Sharma S, et al.: Utility values associated with blindness in an adult population. Br J Ophthalmol 2001, 85:327-331.
15. Sharma S, Brown GC, Brown MM, et al.: The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001, 108:2051-2059.
16. Sharma S, Hollands H, Brown GC, et al.: The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 2001, 12:230-234.
17. Brown GC, Brown MM, Sharma S, et al.: Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiol 2002, 9:1-10.
18. Brown GC, Brown MM, Sharma S, et al.: A cost-utility analysis of interventions for severe proliferative vitreoretinopathy. Am J Ophthalmol 2002, 133:365-372.
19. Sharma S, Brown GC, Brown MM, et al.: Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol 2002, 86:493-496.
20. Brown MM, Brown GC, Sharma S, et al.: Evidence-based medicine, utilities, and quality of life. Curr Opin Ophthalmol 1999, 10:221-226.
21. Redelmeier DA, Detsky AS: A clinician's guide to utility measurement. Prim Care 1995, 22:271-280.
22. Rothwell PM, McDowell Z, Wong CK, et al.: Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997, 314:1580-1583.
23. Brown GC, Brown MM, Sharma S: Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000, 35:127-133.
24. Kassirer JP: Adding insult to injury. Usurping patients' prerogatives. N Engl J Med 1983, 308:898-901.
25. Angell M: Patients' preferences in randomized clinical trials. N Engl J Med 1984, 310:1385-1387.
26. Lunde IM: Patients' perceptions - a shift in medical perspective. Scand J Prim Health Care 1993, 11:98-104.
27. Landy J, Stein J, Brown MM, et al.: Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 2002, 8:543-548.
28. Stein JD, Brown MM, Brown GC, et al.: Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol 2003, 87:8-12. Demonstrates how different subgroups of society can perceive the quality-of-life impact associated with visual loss secondary to age-related macular degeneration.
29. Torrance GW: Utility approach to measuring health-related quality of life. J Chronic Dis 1987, 40:593-603.
30. Torrance GW, Feeny D: Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989, 5:559-575.
31. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med 1977, 296:716-721.
32. Brown GC, Brown MM, Sharma S, et al.: The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 2001, 99:199-203, discussion 203-204.
33. Brown MM, Brown GC, Sharma S, et al.: Quality of life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol 2002, 86:8-11. Evaluates the effect that concomitant, systemic disease has on vision-related quality-of-life utility values.
34. Brown MM, Brown GC, Sharma S, et al.: Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002, 120:481-484.
35. Brown MM, Brown GC, Sharma S, et al.: Quality of life associated with unilateral and bilateral good vision. Ophthalmology 2001, 108:643-647, discussion 647-648. Demonstrates the quality-of-life difference between unilateral and bilateral good vision in terms of utility values.
36. Sharma S, Brown GC, Brown MM, et al.: The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 2000, 11:175-179.
37. Busbee BG, Brown MM, Brown GC, et al.: Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002, 109:606-612, discussion 612-613. Good demonstration of the methodology used to arrive at a cost-utility analysis of a particular intervention.
38. Tengs TO, Adams ME, Pliskin JS, et al.: Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995, 15:369-390.
39. Gage BF, Cardinalli AB, Albers GW, et al.: Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995, 274:1839-1845.
40. Brown MM, Brown GC: Value-based medicine. Br J Ophthalmol 2003, in press.
41. Brown MM, Brown GC, Sharma S: Value-based medicine. Evid Based Eye Care 2003, in press.
42. Russell LB, Gold MR, Siegel JE, et al.: The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276:1172-1177.
43. Weinstein MC, Siegel JE, Gold MR, et al.: Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276:1253-1258.
44. Stark WJ, Sommer A, Smith RE: Changing trends in intraocular lens implantation. Arch Ophthalmol 1989, 107:1441-1444.
45. Steinberg EP, Javitt JC, Sharkey PD, et al.: The content and cost of cataract surgery. Arch Ophthalmol 1993, 111:1041-1049.
46. Norregaard JC, Hindsberger C, Alonso J, et al.: Visual outcomes of cataract surgery in the United States, Canada, Denmark, and Spain. Report From the International Cataract Surgery Outcomes Study. Arch Ophthalmol 1998, 116:1095-1100.
47. Detsky AS, Naglie G, Krahn MD, et al.: Primer on medical decision analysis: Part 1 - getting started. Med Decis Making 1997, 17:123-125.
48. Detsky AS, Naglie G, Krahn MD, et al.: Primer on medical decision analysis: Part 2 - building a tree. Med Decis Making 1997, 17:126-135.
49. Naglie G, Krahn MD, Naimark D, et al.: Primer on medical decision analysis: Part 3 - estimating probabilities and utilities. Med Decis Making 1997, 17:136-141.
50. Krahn MD, Naglie G, Naimark D, et al.: Primer on medical decision analysis: Part 4 - analyzing the model and interpreting the results. Med Decis Making 1997, 17:142-151.
51. Membreno JH, Brown MM, Brown GC, et al.: A cost-utility analysis of therapy for amblyopia. Ophthalmology 2002, 109:2265-2271.
52. Busbee BG, Brown MM, Brown GC, et al.: Cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003, in press.
53. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999, 117:1329-1345.
54. Bressler NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001, 119:198-207.
55. Sharma S, Hollands H, Brown GC, et al.: Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol 2001, 36:332-338.
56. Laupacis A, Feeny D, Detsky AS, et al.: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146:473-481.
57. Wyatt JR, Niparko JK, Rothman M, et al.: Cost utility of the multichannel cochlear implants in 258 profoundly deaf individuals. Laryngoscope 1996, 106:816-821.
58. Smith KJ, Roberts MS: Antiviral therapies for herpes zoster infections. Are they economically justifiable? Pharmacoeconomics 2000, 18:95-104.
59. Jacobson JJ, Schweitzer SO, Kowalski CJ: Chemoprophylaxis of prosthetic joint patients during dental treatment: a decision-utility analysis. Oral Surg Oral Med Oral Pathol 1991, 72:167-177.